Newsroom

September 2019

• Ad hoc release Sep 17, 2019

  Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis

  Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also met [1] Novartis has…
• Press release Sep 13, 2019

  Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis

  Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS)[1]; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20…
• Press release Sep 13, 2019

  New Novartis data show that neuronal and glial filaments, biomarkers of disease activity, have the potential to support decision making in the management of multiple sclerosis (MS) patient

  Monitoring disease activity and treatment effectiveness in MS patients in real-time is a serious challenge for physicians  New data show how the use of two central nervous system-derived…
• Press release Sep 12, 2019

  New Novartis data show Mayzent® can help preserve mobility for longer in patients with secondary progressive multiple sclerosis (SPMS)

  New post hoc statistical analysis of the pivotal EXPAND study at ECTRIMS shows that Mayzent® (siponimod) can help patients keep their mobility for over four years longer on average *[1] …
• 
  Story Sep 11, 2019 Access to Healthcare

  AI is changing the face of healthcare

  AI is already accelerating drug discovery and health delivery. It has great potential to accelerate research, workflow and processes, and even reengineer entire healthcare systems. But what challenges must be addressed first? Shahram Ebadollahi and Ann Aerts share the ideas they discussed at the Intelligent Health summit in Basel this week.

• Press release Sep 10, 2019

  Novartis data at ECTRIMS to highlight innovative approach to reimagining care for people living with multiple sclerosis (MS)

  Novartis will present 34 abstracts from leading MS portfolio, including the highly anticipated results from the Phase III trial of investigational B-cell therapy ofatumumab (OMB157), data for Mayzent…
• Press release Sep 09, 2019

  Novartis data confirm long-term efficacy and safety of Aimovig® for majority of patients with episodic migraine

  The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig® (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years…
• Press release Sep 06, 2019

  Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer

  Currently, there are no targeted therapies approved to treat MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a particularly aggressive form of the diseaseBreakthrough Therapy…
• Press release Sep 05, 2019

  Novartis study shows migraine support in the workplace can improve employee quality of life

  Results from the Migraine Care support program show that employer-initiated educational and counselling support cut migraine-related disability by more than half after 6 months[1]    …
• Press release Sep 03, 2019

  Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine

  Worldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS…
• Press release Sep 02, 2019

  Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings

  Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients[1…
• Press release Sep 01, 2019

  Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint

  Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.…